|
**Overview**: Hyperthyroid Graves Disease Panel**Introduction**: The Hyperthyroid Graves Disease Panel is a diagnostic tool designed to screen for hyperthyroidism (Graves' disease) using serum samples. In India, Graves' disease accounts for ~60-80 percent of hyperthyroidism cases (~1-2 percent prevalence), with high incidence in women of reproductive age, presenting with weight loss, palpitations, tremor, and goiter. High morbidity from underdiagnosis in rural/low-SES patients, limited thyroid labs, delayed carbimazole/radioiodine leading to thyroid storm, atrial fibrillation, or osteoporosis. Per endocrinology practices aligned with ICMR and Endocrine Society of India guidelines, the test employs immunoassay for TSH, free T4, free T3, and anti-TPO over 1-2 days with high accuracy, valuable for confirming autoimmune hyperthyroidism. This diagnostic falls under thyroid screening and targets patients with thyrotoxic symptoms or goiter, addressing accurate detection to guide antithyroid drugs, beta-blockers, or definitive therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise thyroid assessment and reducing complications. Its serum-based approach ensures reliable hormone/antibody measurement.**Other Names**: Graves Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology/immunology, compliant with 2025 standards.**Historical Milestone**: Graves' panel standard; in India, used in thyroid clinics.**Purpose**: The test assesses 4 parameters including TSH to guide hyperthyroidism screening, confirm Graves' disease, inform therapy.**Test Parameters**: 1. TSH, 2. Free T4, 3. Free T3, 4. Anti-TPO.**Pretest Condition**: Fasting 10-12 hours recommended; patients should report thyrotoxic symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on weight loss, palpitations, family thyroid history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated hyperthyroidism including storm, benefits of diagnosis, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent iodine can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Low TSH/high FT4/FT3 + positive anti-TPO confirms Graves', necessitating specialist input.**Specialist Consultation**: Endocrinologists should be consulted for management.**Additional Supporting Tests**: TRAb, thyroid ultrasound for confirmation.**Test Limitations**: Non-specific without TRAb; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Thyroid Studies India 2023. |
